2024-04-04 01:12:23 ET
Summary
- Stoke Therapeutics' stock has surged after positive data from studies of its lead drug candidate, STK-001, in children with Dravet syndrome.
- Dravet syndrome is a severe form of epilepsy that causes multiple seizure types and developmental disabilities.
- Stoke's STK-001 demonstrated substantial reductions in convulsive seizure frequency and improvements in cognition and behavior in patients.
- An approval seems likely, however, investors will need to be patient. An opportunity in ophthalmology and a partnership with Acadia Pharmaceuticals add further value to the company.
Investment Overview
Stoke Therapeutics' ( STOK ) stock has been soaring in response to the positive data the company shared from two open-label Phase 1/2a studies and two open-label extension ("OLE") studies of its lead drug candidate STK-001 in children and adolescents ages 2 to 18 with Dravet syndrome, on March 25th this year....
Read the full article on Seeking Alpha
For further details see:
Stoke Therapeutics: Positive Dravet Data Sends Shares Soaring, One For The Watchlist